Elevation Oncology, Inc. (ELEV)
0.3650
-0.0079 (-2.12%)
Inactive · Last trade price on Jul 22, 2025

Elevation Oncology Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
Net Income
-47.99-44.49-45.7-95.08-32.04-17.27
Upgrade
Depreciation & Amortization
0.020.020.040.030.02-
Upgrade
Other Amortization
-----0.02
Upgrade
Loss (Gain) From Sale of Investments
-1.43-1.45-0.86-0.21--
Upgrade
Stock-Based Compensation
4.374.283.343.211.570.05
Upgrade
Other Operating Activities
0.441.430.70.29--
Upgrade
Change in Accounts Payable
0.060.05-5.860.71-0.035.22
Upgrade
Change in Other Net Operating Assets
5.033.79-7.845.580.31-0.32
Upgrade
Operating Cash Flow
-39.5-36.36-56.18-85.48-30.17-12.3
Upgrade
Capital Expenditures
----0.09--0.07
Upgrade
Investment in Securities
-5.31-8.3711.54-44.31--
Upgrade
Investing Cash Flow
-5.31-8.3711.54-44.4--0.07
Upgrade
Long-Term Debt Issued
---30--
Upgrade
Net Debt Issued (Repaid)
---30--
Upgrade
Issuance of Common Stock
14.7345.16480.0297.060.02
Upgrade
Repurchase of Common Stock
-0.04-0.05-0.02-0.04--
Upgrade
Other Financing Activities
-0.02-0.17--0.47-0.01-0.17
Upgrade
Financing Cash Flow
14.6744.9447.9829.5197.0590.03
Upgrade
Net Cash Flow
-30.140.213.34-100.3766.8877.66
Upgrade
Free Cash Flow
-39.5-36.36-56.18-85.57-30.17-12.37
Upgrade
Free Cash Flow Per Share
-0.67-0.64-1.54-3.68-2.49-15.62
Upgrade
Cash Interest Paid
3.453.533.160.98--
Upgrade
Cash Income Tax Paid
0.040.050.03---
Upgrade
Levered Free Cash Flow
-22.38-22.5-38.12-49.54-18.19-5.83
Upgrade
Unlevered Free Cash Flow
-19.96-20-35.54-48.6-18.19-5.83
Upgrade
Change in Net Working Capital
-4.2-3.6413.71-7.35-0.25-4.98
Upgrade
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q